Please login to the form below

Not currently logged in
Email:
Password:

Cellectis’ Mathieu Simon will serve as interim chief medical officer

He will take over the responsibilities of Loan Hoang-Sayag

Mathieu SimonCellectis has appointed Mathieu Simon to as interim chief medical officer, taking over the role from Loan Hoan-Sayag, who has left the French biopharmaceutical group to “pursue other opportunities”.

As current executive vice president and chief operating officer, Simon was previously chief executive officer of former subsidiary Cellectis Therapeutics has been “instrumental in the strategic and operational management of all therapeutic activities”.

His other roles include senior vice president, global pharma operations for Pierre Fabre and has held numerous senior roles with Wyeth Pharmaceuticals, before it was acquired by Pfizer for $68bn back in 2009.

16th October 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics